ACCENT data presented at 2026 ASCO Gastrointestinal Cancer Symposium

Interim data from Amplia’s Phase 2a ACCENT trial in metastatic pancreatic cancer has been presented at the 2026 American Society for Clinical Oncology: Gastrointestinal Cancer Symposium (ASCO GI) in San Francisco.  

The poster presentation, delivered by Amplia’s Chief Medical Officer Dr Jason Lickliter,  highlights updated efficacy and safety data for narmafotinib in combination with standard chemotherapy (gemcitabine and AbraxaneÒ).

Key points from the poster include: 

• The updated progression-free survival (PFS) is 7.7 months, compared to 5.5 months for Gemcitabine and Abraxane alone 

• The overall response rate (ORR) is 35%; this increases to 42% when including unconfirmed responses 

• Narmafotinib continues to be well tolerated by patients with the adverse effect profile of the narmafotinib-chemotherapy combination similar to chemotherapy alone 

Amplia CEO, Dr Chris Burns, commented: 
"We are pleased to present our research findings to clinicians and scientists at this conference, one of the world’s premier pancreatic cancer meetings. Presenting at ASCO GI positions Amplia among leading biotechnology and pharmaceutical companies internationally and underscores the company's exciting progress in the development of narmafotinib in pancreatic cancer." 

Click to read the ASX release.